Clinical Trial Update: Fluzoparib in Combination With Camrelizumab and Temozolomide in Advanced Melanoma [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 clinical trial is evaluating Fluzoparib in combination with Camrelizumab and Temozolomide for advanced melanoma and is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Camrelizumab (camrelizumab)
• Fluzoparib (fluzoparib)
• Temozolomide (Temozolomide)

Snippet

Sponsor: Jun Guo | Conditions: Melanoma | Phase 1, Phase 2 | Status: RECRUITING